2024 - Novo Nordisk: to present its advances in diabetes

[ad_1]

(CercleFinance.com) – Novo Nordisk announces the presentation of 21 abstracts (7 oral and 14 short) at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD), which will be held from September 9 to 13, 2024 in Madrid.

Data will also be presented at scientific symposia on the COMBINE program with IcoSema for type 2 diabetes, the FLOW trial on the effects of semaglutide 1 mg on the kidneys and amylin treatment for metabolic diseases.

‘This year we are highlighting new data from our pipeline and portfolio in diabetes, obesity, cardiovascular and kidney disease, where we continue to push the boundaries to advance treatments to help more patients,’ said Martin Holst Lange, Executive Vice President and Head of Development at Novo Nordisk.

Did you like this article? Share it with your friends using the buttons below.